Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy

키워드

참고문헌 (90)

1. Pavlova NN, "The emerging hallmarks of cancer metabolism", Cell Metab, 23, pp.27~47 (2016)
2. Hanahan D, "Hallmarks of cancer : new dimensions", Cancer Discov, 12, pp.31~46 (2022)
3. Schiwitza A, "Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer", Immunotherapy, 11, pp.769~782 (2019)
4. Atkins MB, "Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma", Cancer Treat Rev, 70, pp.127~137 (2018)
5. De Re V, "Classical Hodgkin’s lymphoma in the era of immune checkpoint inhibition", J Clin Med, 8, pp.1596~ (2019)
6. Han Y, "PD-1", PD-L1 pathway : current researches in cancer, 2020, pp.10, 727~742
7. Morad G, "Hallmarks of response, resistance, and toxicity to immune checkpoint blockade", Cell, 184, pp.5309~5337 (2021)
8. Conroy M, "Immune-related adverse events and the balancing act of immunotherapy", Nat Commun, 13, pp.392~ (2022)
9. Xia L, "The cancer metabolic reprogramming and immune response", Mol Cancer, 20, pp.28~ (2021)
10. Cong J, "Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression", Cell Metab, 28, pp.243~255 (2018)
11. Ho PC, "Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses", Cell, 162, pp.1217~1228 (2015)
12. Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy : correlation with outcome, "Clin Cancer Res", 2002, 971~979
13. Guo H, "miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1", Tumour Biol, 37, pp.13751~13761 (2016)
14. Won WJ, "Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma", Cell Stress, 3, pp.47~65 (2019)
15. Raber P, "Metabolism of L-arginine by myeloid-derived suppressor cells in cancer : mechanisms of T cell suppression and therapeutic perspectives", Immunol Invest, 41, pp.614~634 (2012)
16. Brand A, "LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells", Cell Metab, 24, pp.657~671 (2016)
17. Watson MJ, "Metabolic support of tumour-infiltrating regulatory T cells by lactic acid", Nature, 591, pp.645~651 (2021)
18. Feng Q, "Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity", Nat Commun, 13, pp.4981~ (2022)
19. Muller AJ, "Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy", Nat Med, 11, pp.312~319 (2005)
20. Opitz CA, "An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor", Nature, 478, pp.197~203 (2011)
21. Uyttenhove C, "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase", Nat Med, 9, pp.1269~1274 (2003)
22. Pilotte L, "Reversal of tumoral immune resistance by inhibition of tryptophan 2, 3-dioxygenase", Proc Natl Acad Sci U S A, 109, pp.2497~2502 (2012)
23. Pallett LJ, "A glutamine tug-of-war: targets to manipulate glutamine metabolism for cancer immunotherapy", Immunother Adv, 1, pp.10~ (2021)
24. Altman BJ, "From Krebs to clinic : glutamine metabolism to cancer therapy", Nat Rev Cancer, 16, pp.619~634 (2016)
25. Liu Y, "High expression of Solute Carrier Family 1, member 5(SLC1A5)is associated with poor prognosis in clear-cell renal cell carcinoma", Sci Rep, 5, pp.16954~ (2015)
26. Lu J, "Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development in vitro and in vivo", Oncotarget, 8, pp.76458~76467 (2017)
27. Guerra L, "Metabolic modulation of immunity : a new concept in cancer immunotherapy", Cell Rep, 32, pp.107848~ (2020)
28. Guo C, "SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity", Nature, 620, pp.200~208 (2023)
29. Chen CL, "Arginine signaling and cancer metabolism", Cancers(Basel), 13, pp.3541~ (2021)
30. Rath M, "Metabolism via arginase or nitric oxide synthase : two competing arginine pathways in macrophages", Front Immunol, 5, pp.532~ (2014)
31. Sun N, "Argininosuccinate synthase 1, arginine deprivation therapy and cancer management", Front Pharmacol, 13, pp.935553~ (2022)
32. Marti ILAA, "Arginine-dependent immune responses", Cell Mol Life Sci, 78, pp.5303~5324 (2021)
33. Geiger R, "L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity", Cell, 167, pp.829~842 (2016)
34. Lamas B, "Altered functions of natural killer cells in response to L-arginine availability", Cell Immunol, 280, pp.182~190 (2012)
35. Guerrero-Rodriguez SL, "Role of CD36 in cancer progression, stemness, and targeting", Front Cell Dev Biol, 10, pp.1079076~ (2022)
36. Feng WW, "CD36-mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-targeted therapies", Cell Rep, 29, pp.3405~3420 (2019)
37. Ladanyi A, "Adipocyteinduced CD36 expression drives ovarian cancer progression and metastasis", Oncogene, 37, pp.2285~2301 (2018)
38. Gharpure KM, "FABP4 as a key determinant of metastatic potential of ovarian cancer", Nat Commun, 9, pp.2923~ (2018)
39. Mukherjee A, "Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance", Cancer Res, 80, pp.1748~1761 (2020)
40. Nieman KM, "Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth", Nat Med, 17, pp.1498~1503 (2011)
41. Zhu G, "Effect of 2-deoxy-D-glucose on gellan gum biosynthesis by Sphingomonas paucimobilis", Bioprocess Biosyst Eng, 42, pp.897~900 (2019)
42. Dey S, "Multifaceted entrancing role of glucose and its analogue, 2-deoxy-Dglucose in cancer cell proliferation, inflammation, and virus infection", Biomed Pharmacother, 156, pp.113801~ (2022)
43. Sasawatari S, "Blockade of N-glycosylation promotes antitumor immune response of T cells", J Immunol, 204, pp.1373~1385 (2020)
44. Liu Y, "A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo", Mol Cancer Ther, 11, pp.1672~1682 (2012)
45. Siebeneicher H, "Iden-tification and optimization of the first highly selective GLUT1 inhibitor BAY-876", ChemMedChem, 11, pp.2261~2271 (2016)
46. Oshima N, "Dynamic imaging of LDH inhibition in tumors reveals rapid in vivo metabolic rewiring and vulnerability to combination therapy", Cell Rep, 30, pp.1798~1810 (2020)
47. Granchi C, "Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A(LDH-A)as starvation agents against cancer cells", J Med Chem, 54, pp.1599~1612 (2011)
48. Maftouh M, "Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia", Br J Cancer, 110, pp.172~182 (2014)
49. Payen VL, "Monocarboxylate transporters in cancer", Mol Metab, 33, pp.48~66 (2020)
50. Kober C, "Targeting the aryl hydrocarbon receptor(AhR)with BAY 2416964 : a selective small molecule inhibitor for cancer immunotherapy", J Immunother Cancer, 11, pp.e007495~ (2023)
51. Reinfeld BI, "Cellprogrammed nutrient partitioning in the tumour microenvironment", Nature, 593, pp.282~288 (2021)
52. Schulte ML, "Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models", Nat Med, 24, pp.194~202 (2018)
53. Ma H, "Inhibition of SLC1A5sensitizes colorectal cancer to cetuximab", Int J Cancer, 142, pp.2578~2588 (2018)
54. Nachef M, "Targeting SLC1A5 and SLC3A2", SLC7A5 as a potential strategy to strengthen anti-tumor immunity in the tumor microenvironment, 2021, pp.12, 624324~
55. Leone RD, "Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion", Science, 366, pp.1013~1021 (2019)
56. Oh MH, "Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells", J Clin Invest, 130, pp.3865~3884 (2020)
57. Edwards DN, "Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer", J Clin Invest, 131, pp.e140100~ (2021)
58. Kuzu OF, "The role of cholesterol in cancer", Cancer Res, 76, pp.2063~2070 (2016)
59. Nomura M, "Fatty acid oxidation in macrophage polarization", Nat Immunol, 17, pp.216~217 (2016)
60. Batista-Gonzalez A, "New insights on the role of lipid metabolism in the metabolic reprogramming of macrophages", Front Immunol, 10, pp.2993~ (2019)
61. Wang Z, "Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade", Nat Med, 25, pp.141~151 (2019)
62. Qiu J, "Acetate promotes T cell effector function during glucose restriction", Cell Rep, 27, pp.2063~2074 (2019)
63. Wu J, "Asparagine enhances LCK signalling to potentiate CD8(+)T-cell activation and anti-tumour responses", Nat Cell Biol, 23, pp.75~86 (2021)
64. Wang T, "Inosine is an alternative carbon source for CD8(+)-T-cell function under glucose restriction", Nat Metab, 2, pp.635~647 (2020)
65. Amitrano AM, "Metabolic challenges in anticancer CD8 T cell functions", Immune Netw, 23, pp.e9~ (2023)
66. Triozzi PL, "Circulating immune bioenergetic, metabolic, and genetic signatures predict melanoma patients response to anti-PD-1 immune checkpoint blockade", Clin Cancer Res, 28, pp.1192~1202 (2022)
67. Varghese S, "The glutaminase inhibitor CB-839(Telaglenastat)enhances the antimelanoma activity of T-cell-mediated immunotherapies", Mol Cancer Ther, 20, pp.500~511 (2021)
68. Ma X, "CD36-mediated ferroptosis dampens intratumoral CD8(+)T cell effector function and impairs their antitumor ability", Cell Metab, 33, pp.1001~1012 (2021)
69. Lin R, "Fatty acid oxidation controls CD8(+)tissue-resident memory T-cell survival in gastric adenocarcinoma", Cancer Immunol Res, 8, pp.479~492 (2020)
70. Lim SA, "Lipid signalling enforces functional specialization of T(reg)cells in tumours", Nature, 591, pp.306~311 (2021)
71. Scharping NE, "Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia", Cancer Immunol Res, 5, pp.9~16 (2017)
72. Afzal MZ, "Efficacy of metformin in combination with immune checkpoint inhibitors(anti-PD-1", anti-CTLA-4)in metastatic malignant melanoma, 2018, pp.6, 64~
73. Afzal MZ, "Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors", Lung Cancer Manag, 8, pp.11~ (2019)
74. Kansal V, "Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models", J Immunother Cancer, 11, pp.e005940~ (2023)
75. Zhang Y, "Enhancing CD8(+)T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy", Cancer Cell, 32, pp.377~391 (2017)
76. Afzal MZ, "Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors", Lung Cancer Manag, 8, pp.11~ (2019)
77. Schlaepfer IR, "CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential", Endocrinology, 161, pp.046~ (2020)
78. Chamoto K, "Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity", Proc Natl Acad Sci U S A, 114, pp.E761~E770 (2017)
79. Yang W, "Potentiating the antitumour response of CD8(+)T cells by modulating cholesterol metabolism", Nature, 531, pp.651~655 (2016)
80. Sun X, "2-Deoxy-D-glucose increases the sensitivity of glioblastoma cells to BCNU through the regulation of glycolysis, ROS and ERS pathways : in vitro and in vivo validation", Biochem Pharmacol, 199, pp.115029~ (2022)
81. Chan DA, "Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality", Sci Transl Med, 3, pp.94~ (2011)
82. Guo L, "Diaminobutoxysubstituted isoflavonoid(DBI-1)enhances the therapeutic efficacy of GLUT1 inhibitor BAY-876 by modulating metabolic pathways in colon cancer cells", Mol Cancer Ther, 21, pp.740~750 (2022)
83. Picard LK, "Inhibition of glucose uptake blocks proliferation but not cytotoxic activity of NK cells", Cells, 11, pp.3489~ (2022)
84. Reckzeh ES, "Inhibition of glucose transporters and glutaminase synergistically impairs tumor cell growth", Cell Chem Biol, 26, pp.1214~1228 (2019)
85. Polanski R, "Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer", Clin Cancer Res, 20, pp.926~937 (2014)
86. Panfili E, "The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1", Front Immunol, 14, pp.1134551~ (2023)
87. Kuhajda FP, "Synthesis and antitumor activity of an inhibitor of fatty acid synthase", Proc Natl Acad Sci U S A, 97, pp.3450~3454 (2000)
88. Lemberg KM, "Clinical development of metabolic inhibitors for oncology", J Clin Invest, 132, pp.e148550~ (2022)
89. Ruiz-Perez MV, "Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma", iScience, 24, pp.102128~ (2021)
90. Feng J, "Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1alpha", PPAR-gamma, J Exp Clin Cancer Res, pp.2020, 39[DOI]

관련 논문AI추천